• Sustainability
  • DE&I
  • Pandemic
  • Finance
  • Legal
  • Technology
  • Regulatory
  • Global
  • Pricing
  • Strategy
  • R&D/Clinical Trials
  • Opinion
  • Executive Roundtable
  • Sales & Marketing
  • Executive Profiles
  • Leadership
  • Market Access
  • Patient Engagement
  • Supply Chain
  • Industry Trends

XtalPi, Eli Lilly Announce AI Robotics Collaboration


Partnership to focus on drug discovery platform.

Robot doctor as a medical assistant on the surgical room. Generative AI. Image Credit: Adobe Stock Images/Elena

Image Credit: Adobe Stock Images/Elena

XtalPi, a pharmaceutical technology company, has announced an AI drug discovery collaboration with Eli Lilly, receiving up to $250 million in milestone payments. Per the agreement, XtalPi will utilize its robotics platform in order to deliver drug candidates for an undisclosed target.

"With a closed loop of AI and quantum physics algorithms working in sync with the data factory of large-scale robotics experiments, XtalPi is uniquely equipped to tackle challenging novel targets,” said Dr. Jian Ma, CEO of XtalPi. “We are honored that Lilly has chosen XtalPi’s AI + robotics drug R&D platform as a partner in achieving more fruitful pharmaceutical innovation and bringing much-needed treatments to patients worldwide."

Reference: XtalPi Announces Collaboration with Lilly, Using AI + Robotics to Uncover First-in-class Therapeutics. May 30, 2023/Xpalti

Related Videos
Related Content